Phase 3 Trial of Acalabrutinib in Combination with Venetoclax, With and Without Obinutuzumab Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

被引：0
|
作者：
Brown, Jennifer R. [1 ]
Eichhorst, Barbara [2 ]
Ghia, Paolo [3 ,4 ]
Kater, A. P. [5 ]
Li, Jianyong [6 ]
Khurana, Sudha [7 ]
Elhamy, Mostafa [7 ]
Wang, Min Hui [7 ]
Seymour, John F. [8 ,9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Hosp Cologne, Cologne, Germany
[3] Univ Vita Salute Raffaele, Milan, Italy
[4] IRCCS Osped San Raffaele, Milan, Italy
[5] Amsterdam UMC, Amsterdam, Netherlands
[6] Nanjing Med Univ, Affiliated Hosp 1, Jiansu Sheng, Peoples R China
[7] Acerta Pharma, San Francisco, CA USA
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
CLL; chronic lymphocytic leukemia; acalabrutinib; Bruton tyrosine kinase inhibitor; combination therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-092
引用
收藏
页码：S221 / S222
页数：2
相关论文
共 50 条
  • [11] Obinutuzumab for previously untreated chronic lymphocytic leukemia
    不详
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (04): : 118 - 120
  • [12] Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Reyes, Carolina
    Gazauskas, Gregory
    Becker, Ursula
    Moreno, Santiago
    Veenstra, David L.
    BLOOD, 2014, 124 (21)
  • [13] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
    Al-Sawaf, Othman
    Robrecht, Sandra
    Zhang, Can
    Olivieri, Stefano
    Chang, Yi Meng
    Fink, Anna Maria
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Sivchev, Liliya
    Niemann, Carsten Utoft
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah
    Manzoor, Beenish S.
    Jawaid, Dureshahwar
    Emechebe, Nnadozie
    Devine, Jacob
    Boyer, Michelle
    Runkel, Eva D.
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    BLOOD, 2024, 144 (18) : 1924 - 1935
  • [14] A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia
    Kay, Neil E.
    Strati, Paolo
    LaPlant, Betsy R.
    Leis, Jose F.
    Nikcevich, Daniel
    Call, Timothy G.
    Pettinger, Adam M.
    Lesnick, Connie E.
    Hanson, Curtis A.
    Shanafelt, Tait D.
    ONCOTARGET, 2016, 7 (48) : 78269 - 78280
  • [15] Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Tadmor, Tamar
    Eyre, Toby A.
    Benjamini, Ohad
    Chaudhry, Arvind
    Shen, Juan
    Leng, Siyang
    Farooqui, Mohammed
    Lavie, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S352 - S353
  • [16] Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia
    Gay, Nathan D.
    Kozin, Eliana
    Okada, Craig
    Danilov, Alexey V.
    Spurgeon, Stephen
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2258 - 2260
  • [17] Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 5-Year Results of the Randomized CLL14 Study
    Al-Sawaf, Othman
    Zhang, Can
    Robrecht, Sandra
    Kotak, Alex
    Chang, Naomi
    Fink, Anna
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl
    Chyla, Brenda
    Eichhorst, Barbara
    Jiang, Yanwen
    Stilgenbauer, Stephan
    Hallek, Michael
    Fischer, Kirsten
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S274 - S275
  • [18] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
    Al-Sawaf, Othman
    Robrecht, Sandra
    Zhang, Can
    Olivieri, Stefano
    Chang, Naomi
    Fink, Anna
    Tausch, Eugen
    Ritgen, Matthias
    Kreuzer, Karl
    Sivcheva, Lilly
    Niemann, Carsten
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah
    Runkel, Eva
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    LEUKEMIA & LYMPHOMA, 2023, 64 : S113 - S113
  • [19] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [20] Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).
    Sharman, Jeff Porter
    Yimer, Habte Aragaw
    Boxer, Michael
    DiBella, Nicholas
    Babu, Sunil
    Li, Jia
    Mun, . . . Yong Jun
    Skettino, Sandra L.
    Danilov, Alexey Valeryevich
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345